Загрузка...

Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland

AIM: This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective. METHODS: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pego...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clinicoecon Outcomes Res
Главные авторы: Purmonen, Timo, Puolakka, Kari, Mishra, Dinesh, Gunda, Praveen, Martikainen, Janne
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2019
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6386207/
https://ncbi.nlm.nih.gov/pubmed/30858713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S192235
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!